**AUB KQ1 Evidence Table (Reference ID #1116)**

| **Study Description** | **Intervention(s)/ Comparator(s)** | **Patient Population** | **Baseline Measure(s)** | **Outcome Measure(s)** | **Overall Quality****Risk of Bias** |
| --- | --- | --- | --- | --- | --- |
| **Author:**Cameron et al., 1990**Country:**United Kingdom**Enrollment** **period:** NR**Intervention** **setting:** Outpatient department**Funding:**Parke-Davis Research Laboratories, Eastleigh, UK**Author industry relationship disclosures:**NR**Study Design:** RCT**Blinding:** NR | **Intervention:**Mefenamic acid, 500 mg three times daily on days 1-5 of menses**Comparator:**Norethisterone, 5 mg twice daily on cycle days 19-26**Groups:****G1:** Mefenamic acid**G2:** Norethisterone2 control cyclesCycle 1Cycle 22 treatment cyclesCycle 3Cycle 4 | **Inclusion criteria:** Heavy menstruation defined by average MBL >80 ml per cycle **Exclusion criteria:** Organic diseaseReceiving medical treatment for menorrhagia**N at enrollment:** **G1:** 17**G2:** 15**N at followup:** **G1:** 17**G2:**15**Age, median years (range):****G1:** 40 (27, 48)**G2:** 40 (21, 51)**BMI:** NR **Height, median cm (range):****G1:** 163 (154, 177)**G2:** 163 (150, 181)**Weight, median kg (range):****G1:** 67 (52, 92)**G2:** 65 (48, 102)**Parity:**NR**Race/ethnicity:** NR | **Bleeding:**MBL measured by alkaline hematin method, median ml (range):**G1:** 123 (86, 237)**G2:** 109 (81, 236)Duration at cycle 1, median days (range):**G1:** 7 (5, 8)**G2:** 7 (5, 10)Duration at cycle 2, median days (range):**G1:** 6 (4, 9)**G2:** 6 (4, 9)Cycle length at cycle 1, median days (range):**G1:** 28 (21, 35)**G2:** 28 (21, 35)Cycle length at cycle 2, median days (range):**G1:** 27 (21, 33)**G2:** 29 (21, 31**)** | **Bleeding:**MBL measured by alkaline hematin method, median ml (range):**G1:** 81 (22, 193)**G2:** 92 (43, 189)**G1 vs. BL:** p<0.001**G2 vs. BL:** p<0.002MBL change, median % (range):**G1:** -24 (-83, 5)**G2:** -20 (-53, 2)**G1 vs. G2:** p>0.1Duration at cycle 3, median days (range):**G1:** 6 (5, 9)**G2:** 6 (4, 8)Duration at cycle 4, median days (range):**G1:** 5 (3, 8)**G2:** 6 (4, 8)**G1 vs. BL:** p<0.01**G2 vs. BL:** p=NSCycle length at cycle 3, median days (range):**G1:** 27 (25, 37)**G2:** 29 (28, 32)Cycle length at cycle 4, median days (range):**G1:** 28 (25, 32)**G2:** 29 (26, 35)**G1 vs. BL:** p=NS**G2 vs. BL:** p=NS**Quality of life:**NR**Pain, n (%):**Abdominal pain:**G1:** 3 (18)**G2:** 3 (20)Headache:**G1:** 4 (24)**G2:** 5 (33)**Sexual function:**NR**Patient satisfaction:**NR**Fertility:**NR**Time to conception:**NR**Additional interventions:** NR**Adverse events, n (%):**Any side effect:**G1:** 10 (59)**G2:** 9 (60)Nausea:**G1:** 2 (12)**G2:** 1 (7)Othera:**G1:** 2 (12)**G2:** 1 (7) | **Overall quality:** Poor**Risk of bias:** Randomization: UnclearAllocation concealment:UnclearSelective reporting:LowBlinding patients/personnel:UnclearBlinding outcome assessment:UnclearIncomplete outcome reporting:LowOther:Low |

**Table Notes:** a Not including abdominal pain or headache.